Antiangiogenesis

Andrew L Feldman, Steven K. Libutti

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

This chapter discusses the finding of tumors that depend on angiogenesis for sustained growth that has prompted intense investigation into the biology of angiogenesis, and the pharmacology of anti-angiogenic agents. Angiogenesis refers to the growth of new capillaries from pre-existing blood vessels. This process is required for a variety of physiologic processes, including normal growth and development, reproduction, and wound healing. These efforts have brought anti-angiogenesis to clinical trials for patients with cancer, and offer promise for non-neoplastic diseases, including arthritis, and several causes of blindness. Exponential progress in the field of molecular analysis, and diagnostics is likely to enhance understanding of the basic biology of angiogenesis, and its inhibition. Meanwhile, the results of the ongoing clinical trials discussed in the chapter are eagerly anticipated. Further study into the use of anti-angiogenic agents as a part of multimodality therapy, the administration of adjuvant antiangiogenic therapy, and the clinical development of antiangiogenic gene therapy, helps to define the role antiangiogenesis that have in the armamentarium of the clinician.

Original languageEnglish (US)
Title of host publicationThe Cytokine Handbook
PublisherElsevier Inc.
Pages1279-1295
Number of pages17
ISBN (Print)9780080518794, 9780126896633
DOIs
StatePublished - Jul 7 2003
Externally publishedYes

Fingerprint

Clinical Trials
Molecular Pathology
Blindness
Growth
Growth and Development
Genetic Therapy
Wound Healing
Arthritis
Reproduction
Blood Vessels
Neoplasms
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Feldman, A. L., & Libutti, S. K. (2003). Antiangiogenesis. In The Cytokine Handbook (pp. 1279-1295). Elsevier Inc.. https://doi.org/10.1016/B978-012689663-3/50060-0

Antiangiogenesis. / Feldman, Andrew L; Libutti, Steven K.

The Cytokine Handbook. Elsevier Inc., 2003. p. 1279-1295.

Research output: Chapter in Book/Report/Conference proceedingChapter

Feldman, AL & Libutti, SK 2003, Antiangiogenesis. in The Cytokine Handbook. Elsevier Inc., pp. 1279-1295. https://doi.org/10.1016/B978-012689663-3/50060-0
Feldman AL, Libutti SK. Antiangiogenesis. In The Cytokine Handbook. Elsevier Inc. 2003. p. 1279-1295 https://doi.org/10.1016/B978-012689663-3/50060-0
Feldman, Andrew L ; Libutti, Steven K. / Antiangiogenesis. The Cytokine Handbook. Elsevier Inc., 2003. pp. 1279-1295
@inbook{01874cf456dd45e48aab8dae4dc817eb,
title = "Antiangiogenesis",
abstract = "This chapter discusses the finding of tumors that depend on angiogenesis for sustained growth that has prompted intense investigation into the biology of angiogenesis, and the pharmacology of anti-angiogenic agents. Angiogenesis refers to the growth of new capillaries from pre-existing blood vessels. This process is required for a variety of physiologic processes, including normal growth and development, reproduction, and wound healing. These efforts have brought anti-angiogenesis to clinical trials for patients with cancer, and offer promise for non-neoplastic diseases, including arthritis, and several causes of blindness. Exponential progress in the field of molecular analysis, and diagnostics is likely to enhance understanding of the basic biology of angiogenesis, and its inhibition. Meanwhile, the results of the ongoing clinical trials discussed in the chapter are eagerly anticipated. Further study into the use of anti-angiogenic agents as a part of multimodality therapy, the administration of adjuvant antiangiogenic therapy, and the clinical development of antiangiogenic gene therapy, helps to define the role antiangiogenesis that have in the armamentarium of the clinician.",
author = "Feldman, {Andrew L} and Libutti, {Steven K.}",
year = "2003",
month = "7",
day = "7",
doi = "10.1016/B978-012689663-3/50060-0",
language = "English (US)",
isbn = "9780080518794",
pages = "1279--1295",
booktitle = "The Cytokine Handbook",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Antiangiogenesis

AU - Feldman, Andrew L

AU - Libutti, Steven K.

PY - 2003/7/7

Y1 - 2003/7/7

N2 - This chapter discusses the finding of tumors that depend on angiogenesis for sustained growth that has prompted intense investigation into the biology of angiogenesis, and the pharmacology of anti-angiogenic agents. Angiogenesis refers to the growth of new capillaries from pre-existing blood vessels. This process is required for a variety of physiologic processes, including normal growth and development, reproduction, and wound healing. These efforts have brought anti-angiogenesis to clinical trials for patients with cancer, and offer promise for non-neoplastic diseases, including arthritis, and several causes of blindness. Exponential progress in the field of molecular analysis, and diagnostics is likely to enhance understanding of the basic biology of angiogenesis, and its inhibition. Meanwhile, the results of the ongoing clinical trials discussed in the chapter are eagerly anticipated. Further study into the use of anti-angiogenic agents as a part of multimodality therapy, the administration of adjuvant antiangiogenic therapy, and the clinical development of antiangiogenic gene therapy, helps to define the role antiangiogenesis that have in the armamentarium of the clinician.

AB - This chapter discusses the finding of tumors that depend on angiogenesis for sustained growth that has prompted intense investigation into the biology of angiogenesis, and the pharmacology of anti-angiogenic agents. Angiogenesis refers to the growth of new capillaries from pre-existing blood vessels. This process is required for a variety of physiologic processes, including normal growth and development, reproduction, and wound healing. These efforts have brought anti-angiogenesis to clinical trials for patients with cancer, and offer promise for non-neoplastic diseases, including arthritis, and several causes of blindness. Exponential progress in the field of molecular analysis, and diagnostics is likely to enhance understanding of the basic biology of angiogenesis, and its inhibition. Meanwhile, the results of the ongoing clinical trials discussed in the chapter are eagerly anticipated. Further study into the use of anti-angiogenic agents as a part of multimodality therapy, the administration of adjuvant antiangiogenic therapy, and the clinical development of antiangiogenic gene therapy, helps to define the role antiangiogenesis that have in the armamentarium of the clinician.

UR - http://www.scopus.com/inward/record.url?scp=3042813035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042813035&partnerID=8YFLogxK

U2 - 10.1016/B978-012689663-3/50060-0

DO - 10.1016/B978-012689663-3/50060-0

M3 - Chapter

AN - SCOPUS:3042813035

SN - 9780080518794

SN - 9780126896633

SP - 1279

EP - 1295

BT - The Cytokine Handbook

PB - Elsevier Inc.

ER -